This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) reachead $37.04 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System
by Zacks Equity Research
Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
by Zacks Equity Research
ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
by Zacks Equity Research
Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.
Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
by Zacks Equity Research
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
New Product Launches to Support HOLX Stock Amid Macro Issues
by Zacks Equity Research
Hologic's Surgical business has been driving strong broad-based performance by expanding access to technologies in new global markets.
TMO Stock Set to Gain From the Launch of New Vulcan Automated Lab
by Zacks Equity Research
Thermo Fisher introduces the Vulcan Automated Lab to transform semiconductor analysis.
Compelling Weight Management Program Data Set to Boost CVS Stock
by Zacks Equity Research
CVS Health shares impressive findings from its Weight Management Program.
BioSpin's Innovations to Support Bruker Shares, Macro Issues to Ail
by Zacks Equity Research
BRKR NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Hims & Hers Stock Gains 8.6% in Three Months: How to Play It?
by Debanjana Dey
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
RMD Stock Likely to Benefit From the New Brand Evolution Strategy
by Zacks Equity Research
In another major brand update, Resmed is likely to unify all the brands under one identity.
Why the Market Dipped But Hims & Hers Health, Inc. (HIMS) Gained Today
by Zacks Equity Research
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $34.71, marking a +0.7% move from the previous day.
EPD Expansion Supports Abbot Stock, Macro Issues Prevail
by Zacks Equity Research
ABT's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
ALGN Stock to Benefit From the Launch of Align X-ray Insights Solution
by Zacks Equity Research
Align Technologies unveils Align X-ray Insights, an AI-backed CADe solution.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNY
Bet on DuPont Analysis & Pick 5 Quality Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap Hims & Hers Health (HIMS), Blue Bird (BLBD), EMCOR Group (EME), EverQuote (EVER) and Sprouts Farmers Market (SFM).
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
by Zacks Equity Research
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%
by Zacks Equity Research
NVO offers Wegovy at a discounted price of $499 per month, which is less than half of its listed price.
Bruker Stock to Benefit From the Launch of X4 POSEIDON Benchtop XRM
by Zacks Equity Research
BRKR unveils X4 POSEIDON advanced XRM for 3D microscopy in industrial and scientific applications.
BSX Stock Set to Gain From the New Agreement to Acquire SoniVie Ltd.
by Zacks Equity Research
Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.